{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:50:07Z","timestamp":1791834607989,"version":"4.3.4"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2505204"],"award-info":[{"award-number":["2022YFC2505204"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2025ZD0550503"],"award-info":[{"award-number":["2025ZD0550503"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.peptides.2026.171524","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:04:49Z","timestamp":1791216289000},"page":"171524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bidirectional pharmacology of GIP receptor targeting in obesity: Historical foundations, mechanistic divergence, and translational boundaries"],"prefix":"10.1016","volume":"201","author":[{"given":"Chenming","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanghai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peirong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongtao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.peptides.2026.171524_bib1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.peptides.2026.171524_bib2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.peptides.2026.171524_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.soard.2022.08.013","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery","volume":"18","author":"Eisenberg","year":"2022","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"11","key":"10.1016\/j.peptides.2026.171524_bib4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.peptides.2026.171524_bib5","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.peptides.2026.171524_bib6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell. Metab."},{"issue":"3","key":"10.1016\/j.peptides.2026.171524_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2026.171524_bib8","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2026.171524_bib9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2026.171524_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102118","article-title":"Glucose-dependent insulinotropic polypeptide (GIP)","volume":"95","author":"M\u00fcller","year":"2025","journal-title":"Mol. Metab."},{"issue":"3","key":"10.1016\/j.peptides.2026.171524_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.peptides.2026.171524_bib12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.peptides.2026.171524_bib13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.str.2021.04.001","article-title":"Investigating GIPR (ant)agonism: a structural analysis of GIP and its receptor","volume":"29","author":"Smit","year":"2021","journal-title":"Structure"},{"key":"10.1016\/j.peptides.2026.171524_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2018.12.001","article-title":"Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism","volume":"20","author":"Mroz","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.peptides.2026.171524_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101945","article-title":"Stimulating intestinal GIP release reduces food intake and body weight in mice","volume":"84","author":"Lewis","year":"2024","journal-title":"Mol. Metab."},{"issue":"12","key":"10.1016\/j.peptides.2026.171524_bib16","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nat. Metab."},{"key":"10.1016\/j.peptides.2026.171524_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102298","article-title":"Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies","volume":"103","author":"Roell","year":"2026","journal-title":"Mol. Metab."},{"issue":"7","key":"10.1016\/j.peptides.2026.171524_bib18","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.peptides.2026.171524_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1172\/JCI25483","article-title":"Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure","volume":"117","author":"Hansotia","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"472","key":"10.1016\/j.peptides.2026.171524_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.peptides.2026.171524_bib21","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnz002","article-title":"Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists","volume":"41","author":"Killion","year":"2020","journal-title":"Endocr. Rev."},{"issue":"8","key":"10.1016\/j.peptides.2026.171524_bib22","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2337\/db25-0393","article-title":"Therapeutic Targeting of the GIP Receptor-Revisiting the Controversies","volume":"74","author":"Campbell","year":"2025","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.peptides.2026.171524_bib23","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2337\/dbi24-0027","article-title":"GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale","volume":"74","author":"Rosenkilde","year":"2025","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.peptides.2026.171524_bib24","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.3390\/jcm14113812","article-title":"The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs","volume":"14","author":"Douros","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.peptides.2026.171524_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-0115(97)00009-8","article-title":"GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro","volume":"69","author":"Gelling","year":"1997","journal-title":"Regul. Pept."},{"key":"10.1016\/j.peptides.2026.171524_bib26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2337\/diabetes.51.3.652","article-title":"Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats","volume":"51","author":"Hinke","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2026.171524_bib27","doi-asserted-by":"crossref","first-page":"758","DOI":"10.2337\/diabetes.48.4.758","article-title":"NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity","volume":"48","author":"O'Harte","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2026.171524_bib28","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1677\/joe.0.1650639","article-title":"Improved glycaemic control in obese diabetic ob\/ob mice using N-terminally modified gastric inhibitory polypeptide","volume":"165","author":"O'Harte","year":"2000","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.peptides.2026.171524_bib29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00125-002-1028-x","article-title":"Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob\/ob) mice: evidence that GIP is the major physiological incretin","volume":"46","author":"Gault","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.peptides.2026.171524_bib30","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.2337\/diabetes.54.8.2436","article-title":"Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes","volume":"54","author":"Gault","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2026.171524_bib31","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1007\/s00125-007-0710-4","article-title":"Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets","volume":"50","author":"Gault","year":"2007","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.peptides.2026.171524_bib32","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1139\/o71-122","article-title":"A gastric inhibitory polypeptide. II. The complete amino acid sequence","volume":"49","author":"Brown","year":"1971","journal-title":"Can. J. Biochem."},{"issue":"5","key":"10.1016\/j.peptides.2026.171524_bib33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre","year":"1973","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.peptides.2026.171524_bib34","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.peptides.2026.171524_bib35","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.2337\/diab.44.10.1202","article-title":"Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor","volume":"44","author":"Gremlich","year":"1995","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.peptides.2026.171524_bib36","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","article-title":"Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain","volume":"133","author":"Usdin","year":"1993","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.peptides.2026.171524_bib37","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s42255-024-01061-4","article-title":"Characterization of genetic variants of GIPR reveals a contribution of \u03b2-arrestin to metabolic phenotypes","volume":"6","author":"Kizilkaya","year":"2024","journal-title":"Nat. Metab."},{"issue":"7","key":"10.1016\/j.peptides.2026.171524_bib38","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab065","article-title":"The Role of Incretins on Insulin Function and Glucose Homeostasis","volume":"162","author":"Holst","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.peptides.2026.171524_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170276","article-title":"The early history of GIP 1969-2000: From enterogastrone to major metabolic hormone","volume":"125","author":"Marks","year":"2020","journal-title":"Peptides"},{"issue":"11","key":"10.1016\/j.peptides.2026.171524_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf1948","article-title":"GIP mediates the incretin effect and glucose tolerance by dual actions on \u03b1 cells and \u03b2 cells","volume":"7","author":"El","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.peptides.2026.171524_bib41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.peptides.2026.171524_bib42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"H\u00f8jberg","year":"2009","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.peptides.2026.171524_bib43","doi-asserted-by":"crossref","first-page":"E224","DOI":"10.1152\/ajpendo.00347.2016","article-title":"Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response","volume":"312","author":"Thondam","year":"2017","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.peptides.2026.171524_bib44","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/db17-0480","article-title":"The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.peptides.2026.171524_bib45","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.peptides.2026.171524_bib46","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell. Metab."},{"issue":"4","key":"10.1016\/j.peptides.2026.171524_bib47","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell. Metab."},{"issue":"2","key":"10.1016\/j.peptides.2026.171524_bib48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bone.2013.07.003","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality","volume":"56","author":"Mieczkowska","year":"2013","journal-title":"Bone"},{"issue":"12","key":"10.1016\/j.peptides.2026.171524_bib49","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.peptides.2026.171524_bib50","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.peptides.2026.171524_bib51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cmet.2024.11.003","article-title":"The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice","volume":"37","author":"Yu","year":"2025","journal-title":"Cell. Metab."},{"issue":"209","key":"10.1016\/j.peptides.2026.171524_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.peptides.2026.171524_bib53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"issue":"10160","key":"10.1016\/j.peptides.2026.171524_bib54","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.peptides.2026.171524_bib55","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.peptides.2026.171524_bib56","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.peptides.2026.171524_bib57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.peptides.2026.171524_bib58","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2337\/db21-0459","article-title":"GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models","volume":"70","author":"Borner","year":"2021","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.peptides.2026.171524_bib59","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2337\/db21-0848","article-title":"GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior","volume":"71","author":"Samms","year":"2022","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.peptides.2026.171524_bib60","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.peptides.2026.171524_bib61","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.686","article-title":"Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index","volume":"42","author":"Speliotes","year":"2010","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.peptides.2026.171524_bib62","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/ng.521","article-title":"Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge","volume":"42","author":"Saxena","year":"2010","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.peptides.2026.171524_bib63","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ng.2606","article-title":"Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture","volume":"45","author":"Berndt","year":"2013","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.peptides.2026.171524_bib64","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/dom.14186","article-title":"Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH(2) on GIP actions in humans","volume":"23","author":"Gasbjerg","year":"2021","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.peptides.2026.171524_bib65","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/osp4.164","article-title":"Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice","volume":"4","author":"Nakamura","year":"2018","journal-title":"Obes. Sci. Pract."},{"key":"10.1016\/j.peptides.2026.171524_bib66","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.molmet.2019.11.018","article-title":"Pharmacological antagonism of the incretin system protects against diet-induced obesity","volume":"32","author":"Svendsen","year":"2020","journal-title":"Mol. Metab."},{"issue":"3","key":"10.1016\/j.peptides.2026.171524_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249239","article-title":"Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism","volume":"16","author":"West","year":"2021","journal-title":"PLoS. One"},{"issue":"5","key":"10.1016\/j.peptides.2026.171524_bib68","article-title":"GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys","volume":"2","author":"Lu","year":"2021","journal-title":"Cell. Rep. Med."},{"key":"10.1016\/j.peptides.2026.171524_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102006","article-title":"AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys","volume":"88","author":"Jensen","year":"2024","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.peptides.2026.171524_bib70","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat. Metab."},{"issue":"9","key":"10.1016\/j.peptides.2026.171524_bib71","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.peptides.2026.171524_bib72","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s42255-025-01294-x","article-title":"GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice","volume":"7","author":"Gutgesell","year":"2025","journal-title":"Nat. Metab."},{"issue":"6","key":"10.1016\/j.peptides.2026.171524_bib73","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s42255-025-01295-w","article-title":"GIPR-Ab\/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice","volume":"7","author":"Liu","year":"2025","journal-title":"Nat. Metab."},{"key":"10.1016\/j.peptides.2026.171524_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s42255-026-01575-z","article-title":"Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism","author":"Lewis","year":"2026","journal-title":"Nat. Metab."},{"key":"10.1016\/j.peptides.2026.171524_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102074","article-title":"Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss","volume":"95","author":"Wean","year":"2025","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.peptides.2026.171524_bib76","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1038\/s41467-020-18751-8","article-title":"Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism","volume":"11","author":"Killion","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.peptides.2026.171524_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102094","article-title":"Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation","volume":"92","author":"Davies","year":"2025","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.peptides.2026.171524_bib78","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/dom.70300","article-title":"A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice","volume":"28","author":"Davies","year":"2026","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.peptides.2026.171524_bib79","doi-asserted-by":"crossref","first-page":"E122","DOI":"10.1152\/ajpendo.00073.2012","article-title":"Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance","volume":"303","author":"J\u00f8rgensen","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.peptides.2026.171524_bib80","doi-asserted-by":"crossref","first-page":"336","DOI":"10.2337\/db22-0568","article-title":"The Importance of Endogenously Secreted GLP-1 and GIP for Postprandial Glucose Tolerance and \u03b2-Cell Function After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy Surgery","volume":"72","author":"Hinds\u00f8","year":"2023","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.peptides.2026.171524_bib81","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/ijo.2016.121","article-title":"Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery","volume":"40","author":"Svane","year":"2016","journal-title":"Int. J. Obes. (Lond. )"},{"key":"10.1016\/j.peptides.2026.171524_bib82","article-title":"Pharmacologic management of weight regain following bariatric surgery","volume":"13","author":"Lucas","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"10.1016\/j.peptides.2026.171524_bib83","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12986-026-01115-2","article-title":"Mechanisms of weight recurrence after bariatric surgery","volume":"23","author":"Yadav","year":"2026","journal-title":"Nutr. Metab. (Lond. )"},{"issue":"6","key":"10.1016\/j.peptides.2026.171524_bib84","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1007\/s11695-016-2152-x","article-title":"Weight Regain Following Sleeve Gastrectomy-a Systematic Review","volume":"26","author":"Lauti","year":"2016","journal-title":"Obes. Surg."},{"issue":"4","key":"10.1016\/j.peptides.2026.171524_bib85","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s11695-024-07137-0","article-title":"Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study","volume":"34","author":"Jamal","year":"2024","journal-title":"Obes. Surg."},{"issue":"1","key":"10.1016\/j.peptides.2026.171524_bib86","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00423-025-03831-4","article-title":"GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis","volume":"410","author":"Tan","year":"2025","journal-title":"Lange Arch. Surg."},{"issue":"12","key":"10.1016\/j.peptides.2026.171524_bib87","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1007\/s11695-025-08414-2","article-title":"Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis","volume":"35","author":"Osorio Manyari","year":"2025","journal-title":"Obes. Surg."},{"issue":"3","key":"10.1016\/j.peptides.2026.171524_bib88","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s11695-025-07733-8","article-title":"Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis","volume":"35","author":"Nie","year":"2025","journal-title":"Obes. Surg."},{"issue":"9","key":"10.1016\/j.peptides.2026.171524_bib89","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1007\/s00464-025-11942-8","article-title":"Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study","volume":"39","author":"Brown","year":"2025","journal-title":"Surg. Endosc."},{"issue":"5","key":"10.1016\/j.peptides.2026.171524_bib90","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/oby.23736","article-title":"Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence","volume":"31","author":"Murvelashvili","year":"2023","journal-title":"Obes. (Silver Spring)"},{"issue":"4","key":"10.1016\/j.peptides.2026.171524_bib91","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s11695-023-06484-8","article-title":"Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study","volume":"33","author":"Jensen","year":"2023","journal-title":"Obes. Surg."},{"issue":"10","key":"10.1016\/j.peptides.2026.171524_bib92","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1007\/s11695-022-06211-9","article-title":"The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis","volume":"32","author":"Lautenbach","year":"2022","journal-title":"Obes. Surg."},{"issue":"4","key":"10.1016\/j.peptides.2026.171524_bib93","doi-asserted-by":"crossref","first-page":"O1","DOI":"10.1002\/oby.22719","volume":"28","author":"Mechanick","year":"2020","journal-title":"Obes. (Silver Spring)"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978126000616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978126000616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:30:36Z","timestamp":1791833436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978126000616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":93,"alternative-id":["S0196978126000616"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2026.171524","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bidirectional pharmacology of GIP receptor targeting in obesity: Historical foundations, mechanistic divergence, and translational boundaries","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2026.171524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"171524"}}